Identification of novel β‐secretase inhibitors through the inclusion of protein flexibility in virtual screening calculations

Alzheimer's disease is a neurodegenerative disorder featuring both the aggregation of extraneuronal amyloid plaques and intraneuronal neurofibrillary tangles. The deposition of Aβ peptides in the brain plays a key role in the onset and progression of this disease, and β‐secretase (BACE‐1) is critical in this process. Thus, the inhibition of this enzyme is an attractive approach to anti‐Alzheimer therapy. So far, the rational design of new BACE‐1 inhibitors has been hampered by the intrinsic flexibility displayed by the enzyme which is not included in standard molecular modeling methods.